MA granted for drug tested in just 34 patients

4 April 2018

An absence of comprehensive data did not prevent Italian family-owned drugmaker Chiesi Farmaceutici from receiving Marketing Authorization (MA) for Lamzede (velmanase alfa).

The MA was granted under European Union (EU) ‘exceptional circumstances’ legislation whereby the applicant is unable to provide comprehensive data on efficacy and safety in normal conditions of use, in this case because the condition concerned is an ultra-rare disorder.

So, after being investigated in just 34 patients, Lamzede has become the first enzyme replacement therapy for the treatment of non-neurological manifestations in patients with mild to moderate alpha mannosidosis (AM), a condition presenting a broad range of symptoms with generally poor long-term prognosis and reduced life expectancy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK